Patent intelligence · AU
AU 2016249784
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
Patent details — AU 2016249784
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Nov 2, 2017
- Expiration
- Oct 28, 2037
- Applicant
- ASTELLAS PHARMA INC [JP]
- CPC classes
- A61K/3939558, A61K/476801, A61K/476851, A61P/104
Quick answer
AU 2016249784 (Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Nov 2, 2017. Expires Oct 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS PHARMA INC [JP]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3939558, A61K/476801, A61K/476851, A61P/104, A61P/3500
More from ASTELLAS PHARMA INC [JP]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2016249784?
AU 2016249784 (Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Nov 2, 2017. Expires Oct 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2016249784?
ASTELLAS PHARMA INC [JP] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2016249784 expire?
Our index shows an expiration date of Oct 28, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.